Clinical trials: Induced Pluripotent Stem Cell (Ips Cell)
Myocardial Ischemia
Clinical Trial of Human (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet for Ischemic Cardiomyopathy
Targeting patients with severe ischemic cardiomyopathy, the purpose of this study is as follows: to confirm short-term efficacy by observing changes and transitions in cardiac function and clinical symptoms compared with each…
- Trial name
- NCT04696328
- Testing
- Human (allogeneic) iPS cell derived-cardiomyocyte sheet
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Osaka University
the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P)
The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).
A Phase I Study to Assess the Safety, Tolerability and Efficacy of dopaminergic neural progenitor cells (XS411CN cell injection) for the treatment of multiple system atrophy Parkinsonian variant (MSA-P).
- Trial name
- NCT07617012
- Testing
- XS411CN Cell Injection
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Depressive Disorder, Treatment-Resistant
In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells
Major depressive disorder (MDD), is a major medical and economic burden for today's society. About 30% of MDD patients develop treatment-resistant depression - TRD with the related sequelae in terms of worse prognosis.
- Trial name
- NCT05887310
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Milano Bicocca
Intellectual Deficiency, Asymptomatic Carrier of the Mutation of the Gene MYT1L
Development of the Tool " iPSC " for the Functional Study of Mutations Responsible for Mental Retardation
According to the World Health Organization (WHO), mental retardation (MR) is defined by an intelligence quotient (IQ) < 70 and touches between 1 to 3 % of the general population.
- Conditions
- Intellectual Deficiency, Asymptomatic Carrier of the Mutation of the Gene MYT1L, Healthy Volunteers
- Trial name
- Rementips (NCT02980302)
- Testing
- Cutaneous biopsy
- Where
- France
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Retinal Dystrophies
iPS Cells of Patients for Models of Retinal Dystrophies
The investigators are focused on inherited retinal dystrophies with an aim to further understand disease pathophysiology and to elaborate novel treatments, as, to date, there is no effective treatment to prevent blindness.
- Trial name
- RETIPS (NCT03853252)
- Testing
- Skin biopsy
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Montpellier
Induced Pluripotent Stem Cells
Stem Cell Study of Genetics and Drug Addiction
Background: Researchers are interested in studying the roles that genes play in drug and alcohol addiction. Genes seem to account for about half of the differences between people who become addicted to drugs and people who do…
- Trial name
- NCT01534624
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Atopic Dermatitis
Induced Pluripotent Stem Cell Derived Exosomes for the Treatment of Atopic Dermatitis
Evaluate the safety, tolerability, and preliminary efficacy of GD-iExo-001 in the treatment of atopic dermatitis
- Trial name
- NCT05969717
- Testing
- GD-iExo-001, normal saline
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Amyotrophic Lateral Sclerosis
Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells
Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation. The major goal of the project is to develop human iPS cells from various types of cell cultures or lines…
- Trial name
- NCT00801333
- Where
- 2 sites in Israel
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Knee Osteoarthritis
A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA
This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It is a dose-escalating, open label study in adult KOA subjects.
- Trial name
- NCR100 (NCT06049342)
- Testing
- NCR100 injection
- Volunteers
- 12 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Retinal Disease, AMD
Cell Collection to Study Eye Diseases
Background: Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye.
- Conditions
- Retinal Disease, AMD, Retinal Degeneration, Retinitis Pigmentosa
- Trial name
- NCT01432847
- Where
- United States
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Heart Failure
Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure
The BioVAT-HF trial will test the hypothesis that cardiomyocyte implantation via engineered heart muscle (EHM), the proposed investigational medicinal product (IMP; designated "Biological Ventricular Assist Tissue" or BioVAT)…
- Trial name
- BioVAT-HF (NCT04396899)
- Testing
- EHM implantation
- Where
- 3 sites in Germany
- Volunteers
- 53 people
- Sponsor
- University Medical Center Goettingen
AMD
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is the leading cause of blindness in the United States. Currently, there is no safe way to obtain cells from the eye to study.
- Trial name
- NCT03372746
- Where
- 14 sites in United States
- Volunteers
- 187 people
- Sponsor
- National Eye Institute (NEI)
Heart Failure
A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)
The purpose of this clinical study is to evaluate the efficacy and safety of intramyocardial injection of human induced pluripotent stem cell-derived cardiomyocyte injection (HiCM-188) in patients with advanced heart failure…
- Trial name
- REVIVE-HEART (NCT07496372)
- Testing
- HiCM-188 therapy, CABG surgery
- Where
- China
- Volunteers
- 80 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Stable Vitiligo
Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Stable Vitiligo
Evaluate the efficacy of induced pluripotent stem cell-derived exosomes (iPSC-Exos) for the treatment of stable vitiligo
- Trial name
- NCT06810869
- Testing
- human induced pluripotent stem cell derived exosomes （GD-iExo-003）
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Second Affiliated Hospital of Wannan Medical College
Parkinson Disease, Idiopathic
An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease
This clinical study is designed to explore the safety and tolerability of UX-DA001. It will also explore if UX-DA001 works to improve motor function in subjects with Parkinson's disease.
- Trial name
- NCT06778265
- Testing
- UX-DA001
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai UniXell Biotechnology Co., Ltd
Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)
A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD
A study to evaluate the safety and preliminary efficacy of iMSC in subjects with SR-aGVHD
- Trial name
- NCT06321198
- Testing
- iMSC
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Anhui Provincial Hospital
Inborn Errors of Metabolism
Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Inborn Errors of Metabolism (iPSC-IEM)
Human induced pluripotent stem cells (iPSCs), are reprogrammed from somatic cells that can self-renew indefinitely and produce different types of cells. They provide human model cell lines for orphan drug development.
- Trial name
- iPSC-IEM (NCT04097275)
- Testing
- Skin biopsy, Withdraw of blood
- Where
- Pakistan
- Volunteers
- 1,000 people
- Sponsor
- CENTOGENE GmbH Rostock
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis
Answer ALS: Individualized Initiative for ALS Discovery
Creation of a large repository of induced pluripotent stem cells (iPSC), bio-fluid samples (blood and spinal fluid (optional)), and cell lines for ALS gene identification.
- Conditions
- Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Flail Arm ALS, Progressive Muscular Atrophy
- Trial name
- AnswerALS (NCT02574390)
- Where
- 8 sites in United States
- Volunteers
- 1,049 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Parkinson Disease
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
The goal of this clinical trial is to assess the safety and tolerability of the surgical transplantation of dopaminergic progenitor cells into the brains of participants with Parkinson's disease.
- Trial name
- NCT06687837
- Testing
- autologous dopaminergic cell implantation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jeffrey S. Schweitzer, MD, PhD
Acute Graft-versus-Host Disease
A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
An open-label, randomized, controlled clinical trial to explore the efficacy and safety of iMSC in preventing the development of acute graft-versus-host disease of degree III-IV in patients after allogeneic hematopoietic stem…
- Trial name
- NCT06949267
- Testing
- iMSC, conventional aGVHD prophylaxis
- Volunteers
- 56 people
- Sponsor
- Ruijin Hospital